Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With § 130a Paragraph 8 Sgb V For The Active Ingredient Rotigotine, Atc N04bc09 For The Period 01.01.2023 - 31.12.2024. / § 130a Paragraph 8 Sgb V Enables Health Insurance Companies And Pharmaceutical Companies To Conclude Framework Discount Agreements On Close The Drugs To Be Dispensed At The Expense Of The Statutory Health Insurance Companies. With Regard To The Relevant Legal Regulations For The Award Of Public Contracts, A Regular Process Of Active Ingredient-Related, Formal Award Procedures Takes Place According To The Regulations Of The 4th Part Of The Gwb By The Dak-Gesundheit. For Pharmaceuticals To Be Specified By The Bidder In Annex 2 To The Contract For The Above-Mentioned Active Ingredient Rotigotine, Atc N04bc09, Dak-Gesundheit Intends To Conclude Drug Discount Agreements With As Many Interested Pharmaceutical Companies As Possible Until New Drug Discount Agreements Come Into Force. A Discount Agreement In The Context Of The Admission Model For The Above The Active Substance Comes Into Force For The First Time On January 1st, 2023 And Ends On December 31st, 2024. Irrespective Of This, It Ends Automatically When The Exclusive Contract Comes Into Force.